Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

Zenas's strong balance sheet, with $301.6M in cash and runway into late 2026, supports aggressive late-stage pipeline ...

Altimmune has shared an update on the metabolic dysfunction-associated steatohepatitis (MASH) study that sank its stock in June. The 48-week readout linked the top dose of the GLP-1/glucagon dual ...

Just days after an upbeat R&D event, Neurocrine Biosciences has found itself having to report a phase 3 failure. | Neurocrine’s Ingrezza, approved to treat certain uncontrolled movements, failed to ...

Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...

The MCU's third (and arguably best) phase of films features some truly stunning shots, so here are some of our favorites from ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The double-blind, randomized, placebo-controlled phase 3 ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Use of alternative endpoints in phase 3 oncology trials ...

Having played a bit of football in my day, I often relate business concepts to sports. Regardless of whether or not you’re a sports fan, a sports metaphor can help take a complicated and cumbersome ...

While the third act of Avengers: Endgame could make this the most entertaining of the third Phase alone, this entry in The ...

The fundraising pace for GeeFi continues to accelerate at an unprecedented rate, with the project announcing today that Phase ...